Alphabet, with a market cap of $2.5 trillion, is a tech giant dominating search, advertising, video, and cloud computing. Revenue hit $96.4 billion in the second quarter, with search revenue jumping 11.7% to $54.2 billion. Google Cloud revenue surged 32% to $13.6 billion, with a backlog of $106 billion.

Alphabet plans to increase capital expenditures to $85 billion by 2025, focusing on cloud and AI. Despite investments, free cash flow hit $66.7 billion. With a “Strong Buy” rating on Wall Street, analysts see an 8.4% upside potential. New AI and cloud investments make Alphabet attractive in big tech.

Eli Lilly, valued at $663 billion, leads in weight-loss and diabetes therapies. Revenue increased by 38% in the second quarter, with key products like Mounjaro and Zepbound driving sales. R&D investment rose by 23%, focusing on oncology and neuroscience. Analysts rate Eli Lilly as a “Strong Buy” with a 32% upside potential.

Eli Lilly offers a mix of short-term growth and long-term potential with its dominance in obesity and diabetes, expanding portfolio, and financial strategy. Analysts predict a 32% increase in stock value. With strong growth prospects, Eli Lilly is positioned for sustained success in the pharmaceutical industry.

Read more at Yahoo Finance: 2 Outstanding ‘Strong Buy’ Stocks to Grab in August